Suppressed autophagy on the account of miR-101 is reported in breast cancer (targeting RAB5A, STMN1 and ATG4D), HCC (through EZH2) [22, 23] and in ischemic liver (via activating mTOR signaling pathway) [41]. Here, EZH2 is linked to breast cancer.